HBI Deals+Insights / News
Global pharma is increasingly viewing emerging markets in three segments, retaining operations hubs and premium specialty markets while exiting older, mass‑market generics. European companies are divesting legacy portfolios to focus on high-growth biologics and precision medicines.





